| |
|
|
|
Sierra Oncology Reports Third Quarter 2021 Results
|
|
Vancouver, BC, December 1, 2021--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, has reported its financial and operating results for the third quarter ended September 30, 2021.
|
|
|
|
|
|
|
|
|
|
|
|
Sierra Oncology Reports Third Quarter 2020 Results
|
|
Vancouver, BC, November 18, 2020--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, reported its financial and operational results for the third quarter ended September 30, 2020.
|
|
|
|
|
|
|
|
|
|
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib
|
|
Vancouver, BC, June 1, 2020--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that Dose Intensity and Long-Term Safety data for momelotinib will be presented at the 25th European Hematology Association (EHA) Virtual Congress.
|
|
|
|
|
|
|
|
Sierra Oncology Reports 2019 Year End Results
|
|
Vancouver, BC, March 5, 2020--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, reported its financial and operational results for the year ended December 31, 2019.
|
|
|
|
|
|
|
|
|
|
Vancouver-based Sierra Oncology Announces 1-FOR-40 Reverse Stock Split
|
|
Vancouver, BC, January 22, 2020--Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that its board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-40.
|
|
|
|
|
|
|
|
Vancouver-based Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial
|
|
Vancouver, BC, November 22, 2019--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, announced that it has launched the MOMENTUM clinical trial for patients with myelofibrosis.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
